Cytotoxic markers associate with protection against malaria in human volunteers immunized with plasmodium Falciparum Sporozoites

Journal of Infectious Diseases

Volumn 210, Issue 10, 2014, Pages 1605-1615

  Bijker, Else M ^a   Teirlinck, Anne C ^a   Schats, Remko ^b   Van Gemert, Geert Jan ^a   Van De Vegte Bolmer, Marga ^a   Van Lieshout, Lisette ^b,c   IntHout, Joanna ^a   Hermsen, Cornelus C ^a   Scholzen, Anja ^a   Visser, Leo G ^b   Sauerwein, Robert W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Infectious Diseases ^*  (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chloroquine; cytotoxicity; degranulation; granzyme Rfvt; immunity; immunization; malaria; Plasmodium; protection; T cells

Indexed keywords

CHLOROQUINE; GRANZYME B; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; BIOLOGICAL MARKER; MALARIA VACCINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNIZATION; INFECTION PREVENTION; MALARIA FALCIPARUM; MOSQUITO BITE; NONHUMAN; PLASMODIUM FALCIPARUM; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SPOROZOITE; ADOLESCENT; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; MALARIA, FALCIPARUM; MALE; MONONUCLEAR CELL; NORMAL HUMAN; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HEALTHY VOLUNTEERS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; SPOROZOITES; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904688978     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu293     Document Type: Article

References (48)

1. WHO. World malaria report 2013. WHO, 2013.
2. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest 2010; 120:4168-78.
3. RTSS Clinical Trials Partnership, Agnandji ST, Lell B, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284-95.
4. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-Attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155-64.
5. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011; 11:57-64.
6. McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum Vaccin 2010; 6:114-23.
7. Butler NS, Vaughan AM, Harty JT, Kappe SH. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol 2012; 33:247-54.
8. Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468-77.
9. Roestenberg M, Teirlinck AC, McCall MBB, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011; 377:1770-6.
10. Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013; 341:1359-65.
11. Bijker EM, Bastiaens GJ, Teirlinck AC, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A 2013; 110:7862-7.
12. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000; 165:1453-62.
13. Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an unnatural immune response. Immunol Rev 2008; 225:272-83.
14. Tsuji M. A retrospective evaluation of the role of T cells in the development of malaria vaccine. Exp Parasitol 2010; 126:421-5.
15. Verhage DF, Telgt DS, Bousema JT, et al. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 2005; 63:52-8.
16. Teirlinck AC, McCall MBB, Roestenberg M, et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog 2011; 7: e1002389.
17. Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993; 80:27-38.
18. Heinze G. A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med 2006; 25:4216-26.
19. R Foundation for Statistical Computing. R: A language and environment for statistical computing. Vienna, Austria. http://www.R-project.org/.
20. Heinze G, Ploner M, Dunkler D, Southworth H. logistf: Firths bias reduced logistic regression. R package version 1.21, 2013. http://CRAN.Rproject. org/package=logistf. Accessed 2 April 2014.
21. Harrell FE Jr. rms: Regression Modeling Strategies. R package version 4.1-3, 2014. http://CRAN.R-project.org/package=rms. Accessed 2 April 2014.
22. Goeman JJ. L-1 Penalized Estimation in the Cox Proportional Hazards Model. Biom J 2010; 52:70-84.
23. Goeman JJ. Penalized R package, version 0.9-42, 2012.
24. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12:77.
25. Ma J, Trop S, Baer S, et al. Dynamics of the major histocompatibility complex class I processing and presentation pathway in the course of malaria parasite development in human hepatocytes: implications for vaccine development. PLoS One 2013; 8:e75321.
26. Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011; 334:475-80.
27. Belnoue E, Costa FT, Frankenberg T, et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004; 172:2487-95.
28. Nganou-Makamdop K, van Gemert GJ, Arens T, Hermsen CC, Sauerwein RW. Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNgamma responses of hepatic CD8+ memory T cells. PLoS One 2012; 7:e36508.
29. Cockburn IA, Amino R, Kelemen RK, et al. In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages. Proc Natl Acad Sci U S A 2013; 110:9090-5.
30. Kimura K, Kimura D, Matsushima Y, et al. CD8+ T cells specific for a malaria cytoplasmic antigen form clusters around infected hepatocytes and are protective at the liver stage of infection. Infect Immun 2013; 81:3825-34.
31. Marshall NB, Swain SL. Cytotoxic CD4 T cells in antiviral immunity. BioMed Research International 2011; 2011:1-8.
32. Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol 2010; 262:89-95.
33. Renia L, Marussig MS, Grillot D, et al. In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. Proc Natl Acad Sci U S A 1991; 88:7963-7.
34. Tsuji M, Romero P, Nussenzweig RS, Zavala F. CD4+ cytolytic T cell clone confers protection against murine malaria. J Exp Med 1990; 172:1353-7.
35. Moreno A, Clavijo P, Edelman R, et al. Cytotoxic Cd4+ T-Cells from a Sporozoite-Immunized Volunteer Recognize the Plasmodium falciparum Cs Protein. Int Immunol 1991; 3:997-1003.
36. Frevert U, Nardin E. Cellular effector mechanisms against Plasmodium liver stages. Cell Microbiol 2008; 10:1956-67.
37. Frevert U, Moreno A, Calvo-Calle JM, Klotz C, Nardin E. Imaging effector functions of human cytotoxic CD4+ T cells specific for Plasmodium falciparum circumsporozoite protein. Int J Parasitol 2009; 39:119-32.
38. Franco A, Barnaba V, Natali P, Balsano C, Musca A, Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988; 8:449-54.
39. Senaldi G, Lobo-Yeo A, Mowat AP, Mieli-Vergani G, Vergani D. Class I and class II major histocompatibility complex antigens on hepatocytes: importance of the method of detection and expression in histologically normal and diseased livers. J Clin Pathol 1991; 44: 107-14.
40. Lobo-Yeo A, Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990; 12:224-32.
41. Herkel J, Jagemann B, Wiegard C, et al. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocytes. Hepatology 2003; 37:1079-85.
42. Renia L, Grillot D, Marussig M, et al. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. J Immunol 1993; 150:1471-8.
43. McCall MB, Sauerwein RW. Interferon-gamma-central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria. J Leukoc Biol 2010; 88:1131-43.
44. Vreden SG, van den Broek MF, Oettinger MC, Verhave JP, Meuwissen JH, Sauerwein RW. Cytokines inhibit the development of liver schizonts of the malaria parasite Plasmodium berghei in vivo. Eur J Immunol 1992; 22:2271-5.
45. Tarun AS, Peng X, Dumpit RF, et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci U S A 2008; 105:305-10.
46. Doolan DL, Southwood S, Freilich DA, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A 2003; 100:9952-7.
47. Adegnika AA, Verweij JJ, Agnandji ST, et al. Microscopic and submicroscopic Plasmodium falciparum infection, but not inflammation caused by infection, is associated with low birth weight. Am J Trop Med Hyg 2006; 75:798-803.
48. Lejeune D, Souletie I, Houze S, et al. Simultaneous determination of monodesethylchloroquine, chloroquine, cycloguanil and proguanil on dried blood spots by reverse-phase liquid chromatography. J Pharm Biomed Anal 2007; 43:1106-15.